Brown Brothers Harriman & Co. Has $507,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

Brown Brothers Harriman & Co. increased its position in AstraZeneca PLC (NASDAQ:AZN) by 7.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 6,506 shares of the company’s stock after acquiring an additional 444 shares during the period. Brown Brothers Harriman & Co.’s holdings in AstraZeneca were worth $507,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Martin Investment Management LLC raised its holdings in shares of AstraZeneca by 2.8% during the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares in the last quarter. Integrated Advisors Network LLC increased its position in AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after buying an additional 13,860 shares during the last quarter. Creative Planning lifted its position in shares of AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after buying an additional 16,692 shares during the last quarter. Northcape Wealth Management LLC bought a new stake in shares of AstraZeneca during the 2nd quarter worth about $269,000. Finally, Cetera Advisors LLC increased its holdings in shares of AstraZeneca by 124.5% during the 1st quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock valued at $6,657,000 after acquiring an additional 54,488 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $66.36 on Wednesday. The firm’s 50-day moving average is $72.94 and its 200-day moving average is $77.65. The company has a market cap of $205.76 billion, a price-to-earnings ratio of 31.75, a PEG ratio of 1.22 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the firm posted $0.87 EPS. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. Equities research analysts anticipate that AstraZeneca PLC will post 4.1 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on AZN. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Finally, TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.